Thirty-two percent of independent pharmacy owners plan to shutter their businesses by the end of 2024, according to a February survey. 

In 2022, overall prescriptions grew 1% from 2019 while mental health-related prescriptions increased 12%, USA Today reported Feb. 29. 

Almost 40% of patients prefer to self-medicate because doing so has worked for them previously, according to a survey published Feb. 27, led by market research and data analytics firm YouGov.

GLP-1s, such as Type 2 diabetes therapies Ozempic and Mounjaro and weight loss drug Wegovy, are expected to bulk up the U.S. economy as more Americans shed pounds. 

In June 2022, the Federal Trade Commission launched a probe into the business practices of pharmacy benefit managers and how they affect drug affordability and access. No PBM has fully complied with the probe, FTC Chair Lina Khan said in…

Viking Therapeutics reported Feb. 27 strong results from a phase 2 trial of a new drug that could rival other GLP-1 medications like Ozempic, Mounjaro and Wegovy.

UnitedHealth Group's Optum Rx is monitoring two drug candidates that might be approved in the next few months, according to its winter 2024 report. 

Mark Cuban Cost Plus Drug Co. will sell Euthyrox, its 21st brand-name drug, in March. 

On Feb. 23, Colorado secured a national first by agreeing to establish a price ceiling on a medication, The Denver Post reported. 

More than two and a half years after the FDA warned about an increased risk of death linked to Pepaxto, a multiple myeloma drug, the agency withdrew the medication's approval Feb. 23.